Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) Income from Continuing Operations (2016 - 2019)

Alterity Therapeutics' quarterly Income from Continuing Operations came in at 3853361.65 in Q4 2019, down 0.58% year-on-year from 3875924.16 in Q4 2018, and down 0.58% quarter-over-quarter from 3831060.31 in Q4 2018.

Alterity Therapeutics has reported Income from Continuing Operations for 4 years, with the latest figure at 3853361.65 in Q4 2019.

  • For the quarter ending Q4 2019, Income from Continuing Operations fell 0.58% year-over-year to 3853361.65; the trailing twelve-month figure through Dec 2019 stood at 13205834.23 (changed N/A YoY), and the FY2025 full-year result was 7779872.4, up 38.27% from the prior year.
  • Income from Continuing Operations for Q4 2019 stood at 3853361.65, down from 3831060.31 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2739462.19 in Q4 2016, with the low at 3853361.65 in Q4 2019.
  • Average Income from Continuing Operations over 4 years is 3301458.56, with a median of 3306505.19 recorded in 2017.
  • Year-over-year, Income from Continuing Operations tumbled 37.71% in 2018 and decreased 0.58% in 2019.
  • Tracing ATHE's Income from Continuing Operations over 4 years: stood at 2739462.19 in 2016, then declined by 1.55% to 2781950.08 in 2017, then tumbled by 37.71% to 3831060.31 in 2018, then declined by 0.58% to 3853361.65 in 2019.
  • The last three Income from Continuing Operations figures came in at 3853361.65 (Q4 2019), 3831060.31 (Q4 2018), and 2781950.08 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - -453.82 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 -3.85 Mn
Dec 31, 2018 -3.83 Mn
Dec 31, 2017 -2.78 Mn
Dec 31, 2016 -2.74 Mn